Kodiak Sciences (NASDAQ:KOD – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 19.52% from the company’s current price.
Kodiak Sciences Price Performance
KOD opened at $2.51 on Tuesday. The business has a fifty day moving average price of $2.68 and a 200 day moving average price of $3.36. Kodiak Sciences has a 12 month low of $1.37 and a 12 month high of $7.77. The stock has a market capitalization of $131.86 million, a price-to-earnings ratio of -0.57 and a beta of 2.35.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01. On average, research analysts anticipate that Kodiak Sciences will post -3.52 earnings per share for the current year.
Institutional Trading of Kodiak Sciences
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
- Five stocks we like better than Kodiak Sciences
- Why Are Stock Sectors Important to Successful Investing?
- Intel’s Spin-Off Strategy: A Bargain Hiding in Plain Sight?
- What is a Stock Market Index and How Do You Use Them?
- Workday’s Next-Gen AI Integration: Perfect Time to Buy the Dip?
- Investing in Commodities: What Are They? How to Invest in Them
- Seize the Growth: Twilio’s AI Innovations Are Driving Huge Upside
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.